Aptevo Therapeutics Inc.
NASDAQ Capital MarketTotal Valuation
Aptevo Therapeutics Inc. carries a market capitalization of 3.56M, placing it among publicly traded companies globally. Its enterprise value stands at -243,336.68, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3.56M |
| Enterprise Value | -243,336.68 |
Share Statistics
Aptevo Therapeutics Inc. currently has 1.20M shares outstanding.
| Shares Outstanding | 1.20M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.88 |
| P/TBV Ratio | 0.88 |
| P/FCF Ratio | -0.14 |
| P/OCF Ratio | -0.14 |
Financial Position
Aptevo Therapeutics Inc. maintains a current ratio of 2.08, meaning it holds 2.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 2.08 |
| Quick Ratio | 1.89 |
| Debt / Equity | 69.67 |
| Debt / EBITDA | -0.16 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -420.34 |
| Return on Assets (ROA) | -175.22 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Aptevo Therapeutics Inc.'s stock has declined approximately -94.41015% over the past 52 weeks. The 50-day moving average sits at 2.17, while the 200-day moving average is 4.70.
| Beta (5Y) | N/A |
| 52-Week Price Change | -94.41015% |
| 50-Day Moving Average | 2.17 |
| 200-Day Moving Average | 4.70 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -26.69M, while operating income came in at -26.89M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -26.89M |
| Pretax Income | -26.41M |
| Net Income | -26.41M |
| EBITDA | -26.69M |
| EBIT | -26.89M |
| Earnings Per Share (EPS) | -31.92 |
Balance Sheet
Aptevo Therapeutics Inc. holds 9.80M in cash and equivalents against 4.21M in total debt, resulting in a net debt position of -9.80M. Total book value stands at 6.04M, with working capital of 5.61M providing operational flexibility.
| Cash & Cash Equivalents | 9.80M |
| Total Debt | 4.21M |
| Net Debt | -9.80M |
| Equity (Book Value) | 6.04M |
| Book Value Per Share | 5.02 |
| Working Capital | 5.61M |
Cash Flow
Aptevo Therapeutics Inc. produced -25.34M in operating cash flow over the past twelve months.
| Operating Cash Flow | -25.34M |
| Capital Expenditures | N/A |
| Free Cash Flow | -25.34M |
| FCF Per Share | -30.63 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -481.41 |
| FCF Yield | -689.92 |
Stock Splits
Aptevo Therapeutics Inc.'s most recent stock split took place on December 30, 2025 with a 18:1 split ratio.
| Last Split Date | 12/30/2025 |
| Split Ratio | 18:1 |
Scores
Aptevo Therapeutics Inc. posts an Altman Z-Score of -33.06, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -33.06 |